Atrinsic, Inc. announced that effective April 4, 2016, Robert Ziroyan ceased serving as interim President and Chief Operating Officer. Mr. Ziroyan's agreement with the company expired on December 31, 2015.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.9 USD | -2.17% |
|
-6.05% | -9.09% |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-9.09% | 4.08M | |
+21.85% | 46.93B | |
+37.63% | 39.08B | |
-8.05% | 38.48B | |
+29.04% | 31.01B | |
-13.75% | 26.14B | |
+10.65% | 25.88B | |
+38.43% | 12.53B | |
-6.92% | 11.36B | |
-12.29% | 10.65B |
- Stock Market
- Equities
- PTIX Stock
- News Protagenic Therapeutics, Inc.
- Atrinsic, Inc. Creases Robert Ziroyan as Interim President and Chief Operating Officer